{"symbol":"REGN","fiscalQuarter":"Q3-2025","reportDate":"2025-10-28","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2025","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 11.82%","keyNumbers":[{"metric":"EPS","actual":"$11.83","expected":"N/A","surprise":"+57.31%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["Management expressed satisfaction with the strong EPS performance.","They highlighted ongoing research and development efforts.","No specific guidance was provided for future quarters."],"summary":"Overall, management conveyed confidence in the company's current trajectory. They emphasized their commitment to innovation and growth."},"guidanceChanges":{"summary":"No guidance data is available for future performance.","changes":[]},"whatItMeans":"Regeneron's strong EPS beat indicates robust profitability, which likely boosted investor confidence, leading to an 11.82% increase in stock price. The lack of revenue data makes it difficult to assess overall performance, but the significant EPS surprise suggests effective cost management or strong sales in key products. Investors may view this as a positive sign for the company's future prospects.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2025 earnings: EPS beat by 57.31%. Stock up 11.82%. Full breakdown."}}